首页 / 院系成果 / 成果详情页

The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients 期刊论文

编号：

4ab7e7e5-5082-4afe-885b-cf2ae07263f6
作者：

Wang, HongNa^[1];Zhu, XiaoYe^[1];Zhu, Ying^[1];Xie, QiongHong(谢琼虹)^[1]Lai, LinYun^[1];Zhao, Miao^[2];Chen, YuanCheng(陈渊成)^[2]Xue, Jun(薛骏)*^[1]Hao, ChuanMing(郝传明)^[1]Gu, Yong(顾勇)^[1]Lin, ShanYan(林善琰)^[1]
语种：

English
期刊：

CLINICAL IMMUNOLOGY ISSN：1521-6616 2015 年 160 卷 2 期 (342 - 348) ; OCT
收录：
关键词：

Cyclophosphamide GSTA1 Pharmacokinetics Pharmacogenomics Lupus nephritis
摘要：

Pulsed low-dose cyclophosphamide (CTX) therapy has become a very effective approach in improving the clinical outcomes of lupus nephritis (LN) patients. However, variations of CTX therapeutic outcomes in LN patients are incompletely understood. We investigated the contributions of known allelic variants to CTX therapy outcomes in 77 LN patients. Then, 22 out of the 77 patients were randomly enrolled to evaluate the pharmacokinetic profiles. LN patients with a GSTA1*A mutation (CT heterozygous) had more risk of non-remission (44% vs. 20%, P = 0.005). Pharmacokinetic data indicated that patients with a GSTA1*A heterozygous variant had a lower exposure to 4-hydroxycyclophosphamide (4OHCTX) compared to wild-type patients (AUC(4OHCTX): 12.8 (9.8, 19.5) vs. 27.5 (18.1, 32.8) h mg/l, P = 0.023). Clinical remission was significantly related to higher exposure of 40HCTX (P = 0.038). In conclusion, LN patients with GSTA1*A heterozygous genotypes had poor CTX treatment remission due to less exposure to activated metabolites of CTX (C) 2015 Elsevier Inc. All rights reserved.
推荐引用方式
GB/T 7714：

Wang Hong-Na,Zhu Xiao-Ye,Zhu Ying, et al. The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients [J].CLINICAL IMMUNOLOGY,2015,160(2):342-348.
APA：

Wang Hong-Na,Zhu Xiao-Ye,Zhu Ying,Xie Qiong-Hong,&Lin Shan-Yan.(2015).The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients .CLINICAL IMMUNOLOGY,160(2):342-348.
MLA：

Wang Hong-Na, et al. "The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients" .CLINICAL IMMUNOLOGY 160,2(2015):342-348.

浏览次数：17  下载次数：0

分享到：

浏览次数：17

下载次数：0

打印次数：0